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ABSTRACT 
Background: Effective treatment of severe gastro-oesophageal reflux disease is available 
through medication or surgery. Postoperative risks have contributed to decreased use of 
antireflux surgery. We aimed to assess short-term mortality following primary 
laparoscopic fundoplication.  
Method: Population-based nationwide Swedish cohort study including all Swedish 
hospitals performing laparoscopic fundoplication, between 1997 and 2013. All patients 
aged 18-65 years with gastro-oesophageal reflux disease who underwent primary 
laparoscopic fundoplication during the study period were included. Main outcome was 
absolute all-cause and surgery-related 90-day and 30-day mortality. Secondary outcomes 
were reoperation and length of hospital stay. Logistic regression was used to calculate 
odds ratios with 95% confidence intervals of reoperation within 90 days and prolonged 
hospital stay (>4 days).  
Results: Of 8947 included patients, 5306 (59.3%) were men, and 551 (6.2%) had a 
significant comorbidity (Charlson comorbidity score >0). Median age at surgery was 48 
years, and median hospital stay was 2 days. Annual rate of laparoscopic fundoplication 
decreased from 15.3 to 2.4 cases per 100 000 inhabitants during the study period, while 
the proportion of patients with comorbidity increased more than 2-fold. All-cause 90- and 
30-day mortality were 0.08% (n=7) and 0.03% (n=3), respectively. Only 1 death (0.01%) 
was directly surgery-related. 90-day reoperation rate was 0.4% (n=39). Comorbidity and 
higher age entailed increased risk for prolonged hospital stay, but not for reoperation.  
Conclusion: This population-based study revealed a remarkably low 90-day mortality 
and reoperation rate following laparoscopic, results which might influence clinical 
decision-making in the treatment of severe gastro-oesophageal reflux disease. 
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INTRODUCTION 
Gastro-oesophageal reflux disease (GORD) is a public health concern, affecting 10% to 
20% of all adults in Western populations, and the rate is increasing.1 GORD is associated 
with limitations to quality of life, high costs for patients, healthcare and society, and a 
risk of complications, including oesophageal adenocarcinoma; an increasingly common 
cancer with poor prognosis.1-4 The two most effective treatment options for severe GORD 
are continuous and long-term medication with proton pump inhibitors (PPIs) or anti-
reflux surgery with laparoscopic fundoplication.2, 3 In current practice, surgery is 
typically only recommended to GORD patients who experience an inadequate response to 
PPIs or who object to long-term use of PPIs. The literature indicates that laparoscopic 
fundoplication may be superior to PPI treatment in terms of reflux symptoms, 
oesophageal acid exposure, overall and GORD associated quality of life, prevention of 
oesophageal adenocarcinoma, and long-term cost effectiveness.3, 5 However, the risk of 
mortality and morbidity following anti-reflux surgery has strongly contributed to its 
considerably decreased use in the last decade,2, 6, 7 although studies suggest that surgical 
therapy might be under-utilized.2, 6-8 The reported overall perioperative and 30-day 
mortality is 0.45%,2, 6, 7, 9 and severe complications occur in up to 4%,2, 3, 10 which is not 
negligible for a benign disorder. However, studies addressing mortality and morbidity 
following anti-reflux surgery are mostly at least a decade old, or have been of the scale of 
examining only single or multiple institutions. Only two population-based studies are 
available, one assessed inpatient postoperative mortality and morbidity,6 and one assessed 
30-day mortality.9 Yet, in an era demonstrating great improvements in postoperative care, 
90-day mortality might be a better assessment of postoperative mortality in upper 
gastrointestinal surgery.11 We aimed to assess 90-day mortality and morbidity after 
primary laparoscopic fundoplication for GORD in a recent and unselected nationwide 
cohort with complete follow-up of all participants. 
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METHODS 
Study design 
This was a nationwide, Swedish population-based cohort study investigating the absolute 
risk of mortality and reoperation up to 90 days following primary laparoscopic 
fundoplication during the study period 1st January 1997 to 31st December 2013. In 
addition, the relative risks of reoperation and prolonged postoperative hospital stay were 
assessed. The study cohort consisted of all patients aged 18 to 65 years who underwent 
laparoscopic fundoplication for a recorded GORD diagnosis in Sweden during the study 
period. Data were collected from nationwide Swedish registries. The unique 10-digit 
personal identity number assigned to each resident in Sweden upon birth or immigration, 
enabled linkages of individuals’ data between registries. The indication for surgery, the 
surgical technique used, as well as cause of death, was validated through retrieval of 
medical records for patients who died within 90 days postoperatively during the study 
period. The study was approved by the Regional Ethical Review Board in Stockholm, 
Sweden (reference number 2014/234-31). 
 
Exposure 
All eligible patients, i.e. those who underwent laparoscopic fundoplication for GORD 
during the study period, were identified from the Swedish Patient Registry. We used 
GORD as a criteria for inclusion to avoid including fundoplication for other indications. 
Excluded were 290 patients without a GORD-related diagnosis recorded, including 8 of 
with a Charlson score >1. None of these patients died within 90 days of surgery. The vast 
majority of these patients had a fundoplication in association with oesophago-gastric 
myotomies, mainly for achalasia. The Patient Registry records in-hospital and outpatient 
care since 1964, and includes discharge diagnoses, comorbidities, surgical procedures, 
hospitalization dates, and demographic data. The coverage of in-hospital care has been 
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nationwide complete since 1987, and the coverage of outpatient specialist care reached 
100% in 2001.12 The documented data regarding both diagnoses and surgical procedures 
have excellent completeness and validity.12, 13 The NOMESCO Classification of Surgical 
Procedures, which provides separate codes for laparoscopic and open anti-reflux 
procedures, was introduced to the Patient Registry in 1997, thus determining the start date 
of the study. Laparoscopic fundoplication was identified using the NOMESCO code 
‘JBC-01’, and reoperations were identified with any NOMESCO code beginning with 
‘JW’. The Patient Registry does not contain data on the subtype of fundoplication 
performed, e.g. procedures according to Nissen, Toupet or others. The data needed to 
calculate the rates of laparoscopic fundoplication per 100 000 inhabitants between 18 and 
65 years in Sweden were derived from the Patient Registry and the Swedish Registry of 
the Total Population. The latter Registry has had 100% nationwide completeness since 
1947.14 GORD diagnoses were retrieved from the Patient Registry (using the 
International Classification of Diseases versions 7-10): GORD, heartburn, hiatal hernia, 
oesophagitis and Barrett’s oesophagus. Also very large hiatal hernias were included. 
 
Outcomes 
Date and causes of death were identified from the Swedish Causes of Death Registry. 
This Registry contains information on all deceased Swedish residents since 1952 with a 
completeness of 99.2%.15 All data in this Registry are coded according to the 
International Classification of Diagnoses system. 
 
Data on the secondary outcomes, i.e. postoperative reoperation and prolonged hospital 
stay, were retrieved from the Patient Registry. Postoperative reoperation was defined as 
any surgery conducted within 90 days following the primary fundoplication. Patients who 
died within 90 days of surgery were excluded from the analyses addressing reoperation. 
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Prolonged hospital stay was defined as duration of stay of 4 or more days following 
laparoscopic fundoplication, which exceeds the routine length of stay.2, 16 Length of 
hospital stay was calculated from the admission and discharge dates in the Patient 
Registry. In order to include any in-hospital days following discharge at another ward or 
hospital, we also included any subsequent in-hospital care following admissions up to 1 
day after discharge from the surgery ward.  
 
Covariates 
The study covariates were sex, age, comorbidity, date of admission, and length of 
hospital stay, all collected from the Patient Registry. Covariates were chosen based on 
known cause-effect relations for increased morbidity and mortality in the previous 
literature. The covariates and the model was determined in the study protocol prior to 
data collection to ensure nominal coverage of the confidence intervals. Comorbidity was 
defined using the Charlson comorbidity score, a well validated composite variable for 
quantification of comorbidity, which is based on specific diagnosis codes.17-20 Patients 
were categorized into three Charlson comorbidity score groups: 0, 1, or >2, a 
categorization that distinguishes the groups regarding risk of mortality.17 
 
Statistical analysis 
We calculated the absolute risk of death and reoperation following laparoscopic 
fundoplication. The low number of deaths prohibited further analyses of short-term 
mortality. A multivariable logistic regression model was used to assess the odds ratio 
(OR) and 95% confidence interval (CI) of reoperation within 90 days after surgery, as 
well as of prolonged length of hospital stay. Adjustments were made for the covariates 
age (continuous variable), sex (male or female), year of surgery (continuous variable), 
and Charlson comorbidity score (0, 1, or >2). Model assumptions and goodness of fit 
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were checked formally and graphically.21 The residuals were plotted against fitted values 
to assess (lack of) fit graphically. We checked for overly influential observations using a 
plot of Cook’s distance versus leverage. Overdispersion was checked by fitting a 
quasibinomial instead of a binomial. In the analysis of hospital stay, a thin plate 
regression spline was used to model the effect of year of surgery. The number of knots 
was checked using a simulation approach. While the exact basis dimension of a thin-plate 
spline is not generally critical, a small enough number ensures computational 
efficiency.22  We used the simulation approach described and implemented in the mgcv 
package for R, as described previously.23 Briefly, an estimate of the residual variance of 
near neighbours was calculated. Residuals were reshuffled a number of times to obtain 
the null distribution of the differencing variance estimator (i.e., there was no pattern 
present in the residuals given the chosen basis dimension). The analyses were conducted 
using the statistical software SAS, version 9.3 (SAS Institute Inc., Cary, NC, USA) and 
R.24 
  
Role of the funding source 
The funding source had no role in the design and conduct of the study; collection, 
management, analysis, and interpretation of the data; or preparation, review, or approval 
of the manuscript. 
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RESULTS 
Study participants 
In total, 8947 patients constituted the laparoscopic fundoplication study cohort with a 
median age at surgery of 48 years, and median length of hospital stay of 2 days (Table 1). 
The majority were men (n=5306, 59.3%), and 5.5% (n=488) and 0.7 % (n=63) had a 
Charlson score of 1 or ≥2, respectively. The annual number of laparoscopic 
fundoplication procedures decreased from 832 in 1997 to 144 in 2013 (Figure 1A), and 
the annual procedures performed per 100 000 inhabitants decreased from 15.3 cases in 
1997 to 2.4 cases in 2013 (Figure 1B). The proportion of women increased from 40.7% in 
1997 to 48.6% in 2013. During the study period, the proportion of patients with a 
Charlson comorbidity score of 1 and >2 increased more than 2-fold and 3-fold, 
respectively (Figure 2). The distribution in age and length of hospital stay remained 
constant throughout the study period.  
 
Mortality  
Seven patients died within 90 days of surgery, of whom 3 died within 30 days, giving 90-
day and 30-day all-cause mortality rates of 0.08% and 0.03%, respectively (Table 1). One 
patient (0.01%) died from a direct surgery-related complication, an acute respiratory 
distress syndrome, 19 days after surgery, which was the only in-hospital death. The 
causes of the other 6 deaths were heart failure (n=2), suicide (n=2), diabetic ketoacidosis 
(n=1), and accidental poisoning (n=1). The indications for surgery and surgical technique 
used among all patients that died within 90 days were validated through medical records, 
and were found to be accurate in all cases. The number of all-cause deaths did not surpass 
1 in any of the 17 years studied (Figure 1A). None of the deceased patients underwent 
reoperation. Compared to the other participants, patients who died within 90 days of 
fundoplication had a longer median hospital stay (11 versus 2 days) and more 
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comorbidities with a Charlson score of 1 (28.6% versus 5.5%) and >2 (14.3% versus 
0.7%), whereas the distribution of sex and age was similar. 
 
Reoperation  
The reoperation rate was 0.4% (n=39) within 90 days of laparoscopic fundoplication, and 
also 0.4% (n=38) within 30 days of surgery. In 1997, 3 reoperations were conducted, 
reaching an annual maximum of 6 in 2000, and with no frequency above 1 per year from 
2008 onwards (Figure 1A). The distribution of age, sex, and comorbidity was similar in 
the 90-day reoperation group and the other study participants, while median length of 
hospital stay was greater in the reoperation group (6 versus 2 days) (Table 1). There were 
no statistically significant associations between age, sex, year of surgery, or comorbidity, 
and risk of reoperation (Table 2).  
 
Prolonged hospital stay 
Comorbidity, female sex, and higher age were associated with an increased risk of 
prolonged hospital stay (Table 2). The risk of prolonged hospital stay was characterized 
by a complex pattern over time, descending from increased risk to decreased risk in the 
early to intermediate years of the study, followed by a slight surge during the most recent 
6 years (Figure 3). Overall the risk declined over the study period, especially from the 
start of the study period to 2005, after 2005 there was a slight increase (Figure 3).  
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DISCUSSION 
This study found a very low 90-day all-cause (0.08%) and procedure-related mortality 
rate (0.01%), and reoperation rate (0.4%) following laparoscopic fundoplication for 
GORD. The increasing proportion of operated patients with comorbidity over time did 
not translate into any increase in mortality, reoperation or hospital stay.  
 
Methodological strengths of this study include the nationwide coverage and population-
based design, including virtually all GORD patients who underwent laparoscopic 
fundoplication in Sweden in 1997-2013, which abates selection bias, facilitates 
generalizability, and provides a large sample size. Moreover, the complete and well-
maintained nationwide registries available in Sweden enabled complete follow-up of all 
participants, thus avoiding loss to follow-up. Among potential weaknesses of the study is 
a risk of clinical selection of relatively healthy patients for surgery, yet often with 
particularly severe GORD. However, the surgery cohort reflects routine clinical practice 
and should have only a limited effect on generalizability of the results. Moreover, the 
increasing presence of comorbidity over time did not increase the risk of unfavourable 
short-term outcomes. Since laparoscopic fundoplication can be performed also for 
indications other than GORD, a GORD diagnosis was required for inclusion. Although 
this makes the study more valid, it also introduces a risk of missing eligible individuals 
who had GORD, but did not have this diagnosis recorded. However, this error should be 
limited since discharge diagnoses are required to be recorded in the hospital discharge 
notes, which are transferred to the Swedish Patient Registry. Although adjustments for 
several potential confounding factors were made, information on some other potential 
confounders was not available, including tobacco smoking, which can increase the risk of 
postoperative complications. However, long-term smoking was indirectly adjusted for 
through adjustment for the Charlson comorbidity score, which included chronic 
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obstructive pulmonary disorder, a proxy diagnosis for tobacco smoking. Moreover, it is 
unlikely that information on tobacco smoking would change any of the main results. 
Finally, owing to the partial lack of data regarding exact date of surgery, the date of 
admission was used as a proxy. This assumption could have resulted in slightly imprecise 
postoperative follow-up dates. 
 
To our knowledge, this is the first study investigating 90-day mortality and morbidity 
rates following laparoscopic fundoplication in unselected GORD patients. A Cochrane 
systematic review including 4 randomized clinical trials, all conducted during 1997-2004 
(total n=519), comparing laparoscopic fundoplication and PPI treatment in GORD 
patients reported 0 inpatient deaths (all trials), 3.7% 90-day reoperation rate (one trial), 
and 0 reoperations within 1 year (two trials).7 Furthermore, a recent large cohort study 
from the United States (n=78 233) conducted in 2005-2010 revealed an inpatient 
mortality of 0.13% (calculated by us),6 and a population-based cohort study from 
Denmark (n=2465) between 1997 and 2005 found a 30-day mortality of 0.45%,9 both 
substantially higher than in our study (0.01%). It was not possible to calculate the 
mortality within 30 or 90 days of surgery in the cohort study from the United States, but 
the inpatient complication rate for each year studied showed a higher peak (8.1% versus 
0.7%) and trough (6.3% versus 0.0%) compared to our study.6 The higher inpatient 
mortality in the previous study might partly be explained by the inclusion of patients of 
older age and with greater comorbidity. Another cohort study from the United States 
(n=7531) performed in 2005-2009, which evaluated mortality in patients aged less than 
70 years, showed a 30-day mortality rate of 0.05%, which is more similar to the present 
study (0.03%). However, that study reported a higher complication rate (1.8%).2 Finally, 
an older Finnish nationwide cohort study (n=6859) conducted in 1992-2001 revealed a 
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30-day mortality rate of 0.04%,10 which is similar to the present study. However, the 
Finnish study did not assess surgery-related or 90-day mortality.  
 
The present study found a higher prevalence of comorbidity in the 7 patients who died 
within 90 days of laparoscopic fundoplication, which indicates that comorbidity should 
be taken into account when the treatment alternatives are considered. However, the 
increasing proportion of patients with comorbidity during the study period did not seem 
to have affected the risk of poor 90-day outcomes.6 Possible explanations are 
advancement in the modern laparoscopic fundoplication technique, enhanced surgeon 
skills, centralization of services or improvements in perioperative healthcare. 
 
The increased risk of prolonged hospital stay with higher age and comorbidity in this 
study could be explained by their greater disposition to postoperative complications and 
slower recovery compared to younger and fitter patients. Speculatively, a higher 
proportion of women with obesity and increased length of surgery could explain the 
higher risk of prolonged hospital stay found in female patients, since these factors 
correlate with prolonged hospital stay in other upper gastrointestinal surgery patients.25  
 
A decreased use of fundoplication with calendar time has also been reported in the United 
States, where the use of anti-reflux surgery declined from 15.7 to 5.3 operations per 
100,000 inhabitants between 1999 and 2010.6, 26 This decline could be attributed to the 
increased use of PPIs since the early 2000s, an easily accessible drug proven to be 
effective in reflux control and with a well-documented and safe profile.3, 27 In addition, 
the potential risks of mortality and morbidity associated with anti-reflux surgery appear 
to have led general practitioners, gastroenterologists, and possibly also surgeons to 
predominantly favour PPIs over surgery for GORD treatment. Yet, both treatment options 
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can effectively counteract GORD and improve quality of life, although surgery appears to 
be slightly superior in these respects.3 Recurrence of GORD is similarly common 
following both treatments,3 while surgery might be more effective in preventing 
oesophageal adenocarcinoma than PPI use.5 Moreover, surgery seems to be more costly 
in the short term, but perhaps more cost-effective in the long term.3 In addition, concerns 
regarding increased risk of osteoporosis, bone fractures, and Clostridium difficile-
associated diarrhoea following long-term treatment with PPIs have arisen.3  
 
This study demonstrates that laparoscopic fundoplication offers a remarkably safe 
alternative to long-term PPI therapy for severe GORD, with a risk profile similar to other 
common laparoscopic procedures for benign diagnoses, i.e. appendectomy and 
cholecystectomy.2 The low risk might at least partly be due to the increased specialization 
of surgeons involved in minimally invasive upper gastrointestinal surgery. The slight 
superiority of laparoscopic fundoplication treatment, along with the treatment’s safe 
profile, and the increasingly recognized complications of long-term PPI use, argue for 
adopting a decrease in the threshold for recommending laparoscopic fundoplication in 
severe GORD patients, particularly in fit patients aged below 65 years. 
 
In conclusion, this large and population-based cohort study with complete follow-up 
shows a remarkably low surgery-related and all-cause mortality and reoperation rate 
within 90 days following primary laparoscopic fundoplication for GORD. These results 
suggest that laparoscopic fundoplication can be recommended as a safe alternative to PPI 
treatment in fit patients aged below 65 years, at least in the short-term perspective.  
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Table 1. Characteristics of 8947 patients who underwent laparoscopic fundoplication for 
gastro-oesophageal reflux disease during 1997-2013 in Sweden. 
 
 
 
 
 
 
 
 
 
 
 
 
 
* A composite variable for quantification of general comorbid status.  
 All patients 
Number (%) 
90-day death 
Number (%) 
90-day reoperation 
Number (%) 
Total 8947 (100.0) 7 (0.08) 39 (0.4) 
Age at surgery, median years 
(Interquartile range) 
48 (38-55) 42 (41-61) 51 (39-56) 
Sex    
   Male 5306 (59.3) 4 (57.1) 21 (53.9) 
   Female 3641 (40.7) 3 (42.9) 18 (46.1) 
Comorbidity (Charlson score)*     
   0 8396 (93.8) 4 (57.1) 35 (89.7) 
   1 488 (5.5) 2 (28.6) 4 (10.3) 
   ≥2 63 (0.7) 1 (14.3) 0 (0.0) 
Time period for surgery    
   1997-2002 5287 (59.1) 2 (28.6) 22 (56.4) 
   2003-2008 2853 (31.9) 2 (28.6) 14 (35.9) 
   2009-2013 807 (9.0) 3 (42.9) 3 (7.7) 
Length of stay, median days 
(Interquartile range) 
2 (1-3) 11 (3-19) 6 (3-10) 
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Table 2. Odds ratio (OR) and 95% confidence interval (CI) of 90-day reoperation and 
prolonged hospital stay following laparoscopic fundoplication for gastro-oesophageal 
reflux disease (n=8947).  
 
 
 
 
 
 
 
 
 
* Adjusted for sex, comorbidity score, year of surgery, and age at surgery. 
╫ Adjusted by spline (approximate significance of the smooth terms: p < 2x10-16). 
  
 90-day reoperation 
OR (95% CI) 
Adjusted* 
Prolonged hospital stay 
OR (95% CI) 
Adjusted* 
Age at surgery 1.01 (0.98-1.04) 1.01 (1.00-1.01) 
Year of surgery 1.01 (0.94-1.09) ╫ 
Sex   
   Female Reference Reference 
   Male 0.84 (0.44-1.61) 0.76 (0.68-0.86) 
Charlson score   
   0 Reference Reference 
   1 1.86 (0.65-5.33) 1.36 (1.04-1.66) 
   ≥2 Not applicable 2.27 (1.30-4.00) 
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Figure 1A. Laparoscopic fundoplications performed in Sweden in 1997-2013. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total, N 832 975 910 935 895 740 659 631 566 439 331 227 182 183 162 136 144
Male, N
         (%)
495 
(59.5)
580 
(59.5)
581 
(63.9)
581 
(62.1)
546 
(61.0)
455 
(61.5)
378 
(57.4)
387 
(61.3)
347 
(61.3)
237 
(54.0)
168 
(50.8)
120 
(52.9)
99 
(54.4)
110 
(60.1)
81 
(50.0)
67 
(49.3)
74 
(51.4)
90-day reoperation, N 3 4 2 6 2 5 3 3 3 2 2 1 1 0 0 1 1
90-day death, N 0 1 0 0 1 0 0 0 1 0 1 0 0 1 1 1 0
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Figure 1B. Rate of laparoscopic fundoplications per 100 000 inhabitants.  
 
  
Male rate 18.0 21.0 22.0 20.9 19.5 16.2 13.4 13.6 12.1 8.2 5.8 4.1 3.3 3.7 2.7 2.2 2.5
Female rate 12.6 14.7 12.2 13.1 12.8 10.4 10.2 8.8 7.9 7.2 5.8 3.8 2.9 2.5 2.8 2.4 2.4
Total rate 15.3 17.9 16.7 17.0 16.2 13.3 11.8 11.3 10.0 7.7 5.8 3.9 3.1 3.1 2.7 2.3 2.4
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Figure 2. Distribution of comorbidity (Charlson comorbidity score)* in patients with 
gastro-oesophageal reflux disease who underwent laparoscopic fundoplication. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* A composite variable for quantification of general comorbid status. 
  
Charlson score >2 
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Figure 3. Adjusted odds ratios (black line) with 95% confidence intervals (grey area) of 
prolonged hospital stay over time following laparoscopic fundoplication among patients 
with gastro-oesophageal reflux disease. 
 
 
 
 
 
 
 
 
 
 
* Adjusted for sex, comorbidity score, and age at surgery 
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